You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Transcript

John: When I got diagnosed with AML ah nobody in my family had it.

John: I was told it was pretty rare and fast-moving.

Cherie: It was daunting, it was enriching.

Cherie: We learned a lot, and in many ways we became closer.

John: Going in there I knew I was on a clinical trial.

Cherie: We were just so blessed to be there at the right time at the right place and have a spot that they wanted an old man to try.

John: Being on a clinical trial was… well it saved me, really.

John: Being in the hospital you know you’re going to have time other than being interrupted every four hours for a lot of things and I decided I’m going to keep a log of what happens. You-you know you’re going to have time in between and so I did a lot of walking and they told me when I checked into that hospital that 11 times around the out- the per-perimeter was a mile. So I set goals, I’m gonna do my exercise.

John: There were a few days where I had trouble getting up and ah I did walk around but I didn’t record… I mentioned that I didn’t do any laps. What I call laps are when I was really moving… and ah I did get up and walk around very slowly and… those days I didn’t do much. But I had to try and do something.

John: My advice for somebody going through this is have the support, have a positive positive attitude, keep in shape, the best shape you can be.

John: Ah We - we look at it like it’s a new day every day.

WHAT IS VYXEOS?

VYXEOS is a prescription intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders, have a specific genetic mutation, or have certain abnormal blood cells (also called AML with myelodysplasia-related changes, AML-MRC).

IMPORTANT SAFETY INFORMATION

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.